



## Current Efforts for Development of Novel Therapeutics to Combat Antibiotic Resistance

Guest Editor:

**Prof. Dr. Berthony Deslouches**

School of Medicine, University of  
Pittsburgh, Pittsburgh, PA, USA

[tdesl19@pitt.edu](mailto:tdesl19@pitt.edu)

Deadline for manuscript  
submissions:

**31 December 2021**

### Message from the Guest Editor

Dear Colleagues,

While most public health efforts have been directed towards the COVID-19 pandemic in the last two years, it is imperative that we continue to address other public health challenges. Among these challenges is the crisis created by antibiotic resistance, which requires a comprehensive multipronged approach. An important consideration is the development of therapeutics with novel mechanisms. It is in this context that we are presenting this Special Issue of *Antibiotics* to review the progress on novel approaches to antimicrobial therapy and the prospects for new therapeutics for overcoming resistance to traditional antibiotics.





## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:**— free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and many other databases.

**Journal Rank:** JCR - Q2 (*Infectious Diseases*) / CiteScore - Q2 (*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

*Antibiotics*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
Fax: +41 61 302 89 18  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[@antibioticsmdpi](https://twitter.com/antibioticsmdpi)